Correlation Between Unicycive Therapeutics and Mereo BioPharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Unicycive Therapeutics and Mereo BioPharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Unicycive Therapeutics and Mereo BioPharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Unicycive Therapeutics and Mereo BioPharma Group, you can compare the effects of market volatilities on Unicycive Therapeutics and Mereo BioPharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Unicycive Therapeutics with a short position of Mereo BioPharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Unicycive Therapeutics and Mereo BioPharma.

Diversification Opportunities for Unicycive Therapeutics and Mereo BioPharma

-0.68
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Unicycive and Mereo is -0.68. Overlapping area represents the amount of risk that can be diversified away by holding Unicycive Therapeutics and Mereo BioPharma Group in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mereo BioPharma Group and Unicycive Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Unicycive Therapeutics are associated (or correlated) with Mereo BioPharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mereo BioPharma Group has no effect on the direction of Unicycive Therapeutics i.e., Unicycive Therapeutics and Mereo BioPharma go up and down completely randomly.

Pair Corralation between Unicycive Therapeutics and Mereo BioPharma

Given the investment horizon of 90 days Unicycive Therapeutics is expected to generate 1.57 times more return on investment than Mereo BioPharma. However, Unicycive Therapeutics is 1.57 times more volatile than Mereo BioPharma Group. It trades about 0.23 of its potential returns per unit of risk. Mereo BioPharma Group is currently generating about -0.04 per unit of risk. If you would invest  38.00  in Unicycive Therapeutics on September 12, 2024 and sell it today you would earn a total of  42.00  from holding Unicycive Therapeutics or generate 110.53% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Unicycive Therapeutics  vs.  Mereo BioPharma Group

 Performance 
       Timeline  
Unicycive Therapeutics 

Risk-Adjusted Performance

18 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Unicycive Therapeutics are ranked lower than 18 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental indicators, Unicycive Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.
Mereo BioPharma Group 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Mereo BioPharma Group has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's technical and fundamental indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors.

Unicycive Therapeutics and Mereo BioPharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Unicycive Therapeutics and Mereo BioPharma

The main advantage of trading using opposite Unicycive Therapeutics and Mereo BioPharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Unicycive Therapeutics position performs unexpectedly, Mereo BioPharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mereo BioPharma will offset losses from the drop in Mereo BioPharma's long position.
The idea behind Unicycive Therapeutics and Mereo BioPharma Group pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.

Other Complementary Tools

CEOs Directory
Screen CEOs from public companies around the world
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges